At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 29, 2026 at 12:30 ET
MannKind announced FDA approval of Afrezza (inhaled insulin) for pediatric patients aged 6+ with type 1 and type 2 diabetes. This expands Afrezza's addressable population by >350,000 US children/adolescents with diabetes and represents a significant label expansion for MannKind's only marketed product. The approval is based on the Phase 3 INHALE-1 trial and 20+ years of safety data.
- FDA approved Afrezza for children/adolescents aged 6+ with type 1 and type 2 diabetes
- Over 350,000 US children/adolescents have diabetes, mostly type 1 requiring lifelong insulin
- Approval supported by Phase 3 INHALE-1 trial and 20+ years of clinical data
- Eligible patients pay $35/month or less through MannKind Cares
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access